Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2014) 3 PP297 | DOI: 10.1530/boneabs.3.PP297

Osteoporosis: treatment

Contribution of circulating sclerostin and estradiol for inadequate response to bisphosphonate therapy in women with postmenopausal osteoporosis

M Muñoz-Torres1,2, A Díez-Pérez1,3, J M Olmos1,4, X Nogués1,3, M Sosa5, M Díaz-Curiel1,6, J L Pérez-Castrillón1,7, R Pérez-Cano1,8, A Torrijos1,9, E Jodar1,10, L Del Rio1,11, J R Caeiro-Rey1,12, V Ávila Rubio1, A García-Martín1,2, R Reyes-García1,2, B García-Fontana1,2, J González-Macías1,4 & S Morales-Santana1,2

17 views


1RETICEF, Instituto de Salud Carlos III, Madrid, Spain; 2Bone Metabolic Unit, Endocrinology Division (RETICEF), Hospital Universitario San Cecilio, Granada, Spain; 3Department of Internal Medicine, Hospital del Mar-IMIM-UAB, Barcelona, Spain; 4Department of Internal Medicine, Hospital Universitario Marqués Valdecilla, Santander, Spain; 5Osteoporosis Research Group, Universidad de Las Palmas de Gran Canaria, LasPalmas de Gran Canaria, Spain; 6Department of Internal Medicine, Fundación Jiménez Díaz, Madrid, Spain; 7Department of Internal Medicine, Hospital Universitario Río Ortega, Valladolid, Spain; 8Department of Internal Medicine, Hospital Virgen Macarena, Sevilla, Spain; 9Department of Reumatology, Hospital La Paz, Madrid, Spain; 10Department of Endocrinology, Hospital Universitario Quirón, Madrid, Spain; 11CETIR Medical Center, Barcelona, Spain; 12Trabeculae, Ourense, Spain.


Bisphosphonate treatment reduces fracture risk in women with postmenopausal osteoporosis. However, some patients have an inadequate response to treatment. Estradiol and sclerostin play an important role in bone metabolism. Sclerostin is an endogenous inhibitor of osteoblastic activity and estrogen deficiency increases osteoclast activity and bone resorption.

We examined the influence of both measures on fracture incidence in postmenopausal osteoporosis in 120 women on bisphosphonate therapy. Patients were classified in adequate responders (AR, n=66) without incident fractures during 5 years of treatment and inadequate responders (IR, n=54), with incident fractures between 1 and 5 years of treatment. Several variables were measured; anthropometric, biochemical, bone mineral density (DXA), structural analysis of the proximal femur and structural/fractal analysis of the distal radius. Circulating sclerostin concentrations were measured by ELISA and 17β-estradiol levels by RIA based on ultrasensitive methods.

In AR group, sclerostin serum levels were significantly lower (P=0.02) and estradiol concentrations significantly higher (P=0.023) than IR group. In a logistic regression model the independent predictors of inadequate response were: previous history of fragility fracture (OR 11.27, 95% CI 1.88–67.34, P=0.008) and sclerostin levels (OR 1.11, 95% CI 1.02–1.20, P=0.011). Estradiol levels were protective (OR 0.93, 95% CI 0.86–1.01, P=.09). We observed a nonlinear, inverted U-shaped relation between estradiol and sclerostin levels. Lower sclerostin levels were found at both low and high estradiol levels.

In conclusion, sclerostin and estradiol circulating levels are related to inadequate response to treatment with bisphosphonates in women with postmenopausal osteoporosis.

Volume 3

European Calcified Tissue Society Congress 2014

Prague, Czech Republic
17 May 2014 - 20 May 2014

European Calcified Tissue Society 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.